Stem cell therapy for chronic diffuse liver lesions: main symptoms and causes

Area of Science:

• Hepatology
• Biotechnology
• Gastroenterology

Background:

• Chronic liver damage, including fibrosis and cirrhosis, presents a significant challenge in gastroenterology with high socio-economic impact.
• The progressive nature of chronic hepatitis necessitates the development of novel therapeutic strategies to improve patient outcomes.

Purpose of the Study:

• To identify and evaluate emerging biotechnological treatments for diffuse liver diseases.
• To enhance patient survival rates, particularly among the active, working-age population affected by liver conditions.

Main Methods:

• A meta-analysis of existing studies on cellular technologies for liver disease treatment was conducted.
• Theoretical scientific methods including analysis, generalization, questioning, and systematization were employed.

Main Results:

• The study reviewed advancements in cellular therapies, focusing on stem cell mechanisms and transdifferentiation in hepatology.
• Potential risks associated with cell therapy, such as pro-oncogenic effects and increased fibrosis, were examined.

Conclusions:

• Cell therapy utilizing embryonic, mononuclear, and mesenchymal stromal cells represents a cutting-edge field in biotechnology and medicine.
• This therapy holds promise for regulating intercellular interactions, cell death, and fibrogenesis in chronic liver diseases, making it a relevant and forward-looking approach in hepatology.